Abstract
Myofibroblasts produce desmoplastic stroma around tumors and have emerged as therapeutic targets in pancreatic ductal adenocarcinoma (PDAC) and other cancers. Differentiation of pancreatic stellate cells (PSCs) into myofibroblasts is inhibited by the estrogen-receptor modulator, tamoxifen, which activates a G-protein-coupled receptor (GPCR) for estrogen (GPER). This negatively regulates actomyosin contractility and downstream mechanosensitive signaling to profoundly alter the tumor microenvironment, which appears less fibrotic, less immunosuppressive, and more vascularized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
